ARTICLE | Company News
Alnylam, Arrowhead deal
January 16, 2012 8:00 AM UTC
Alnylam granted Arrowhead an exclusive, worldwide license to IP covering an RNAi therapeutic to treat HBV infection. Alnylam is eligible for milestones and royalties. Additionally, Arrowhead granted A...